Metabolic diseases, particularly
type 2 diabetes and obesity, affect millions of people worldwide and continue
to pose major challenges for healthcare systems. Despite existing treatment
options, there remains a strong need for therapies that provide more effective,
comprehensive, and long-term metabolic control.
Mazdutide represents a new stage in
the scientific approach to the treatment of metabolic diseases. It is the
world’s first approved dual GCG/GLP-1 receptor agonist, and its clinical
results have drawn significant attention from the global scientific community.
What Is GCG/GLP-1 and How Does It Work?
Traditional
GLP-1–based therapies primarily focus on blood glucose regulation. Mazdutide,
however, is designed to activate two complementary metabolic pathways at the
same time:
- GLP-1
(Glucagon-Like Peptide-1)
A hormone secreted in the intestines that enhances insulin secretion, lowers blood glucose levels, regulates appetite, and supports weight loss. - GCG (Glucagon)
A hormone that primarily acts on the liver, increasing energy expenditure and promoting fat metabolism.
By simultaneously activating both
GCG and GLP-1 receptors, mazdutide enables more effective glycemic control and
weight reduction, while also supporting broader improvements in metabolic
health.
Phase 3 Clinical Evidence
Mazdutide has been evaluated in two
large Phase 3 clinical studies, DREAMS-1 and DREAMS-2, conducted in adults with
type 2 diabetes. In these studies, mazdutide was assessed both as monotherapy
and in combination therapy. Across both trials, mazdutide demonstrated
statistically significant reductions in HbA1c and meaningful body weight
reduction compared with placebo or dulaglutide 1.5 mg. In addition to glycemic
control and weight loss, favorable changes were observed in multiple
cardiometabolic parameters, including:
- Fasting plasma glucose,
- Blood pressure,
- Lipid profiles,
- Waist circumference, and
- Liver enzyme levels.
These results indicate that
mazdutide offers benefits that extend beyond glucose lowering, contributing to
comprehensive metabolic risk reduction.
Safety Profile
Mazdutide has demonstrated a
favorable safety profile in Phase 3 clinical trials. The most commonly reported
adverse events were mild-to-moderate gastrointestinal effects, primarily
occurring during dose escalation. No severe hypoglycemic events were reported.
What Could This Therapy Become in the Future?
Mazdutide
is not limited to glycemic control alone. Ongoing clinical development aims to
explore its broader potential in metabolic diseases. To date, mazdutide has
been evaluated in a total of seven Phase 3 clinical studies. The first five
studies have successfully met their primary endpoints, while two Phase 3 trials
are currently ongoing:
- GLORY-3: A Phase 3
study comparing mazdutide with semaglutide in adults with overweight or
obesity.
- GLORY-OSA: A Phase
3 study evaluating mazdutide in adults with obesity and obstructive sleep
apnea (OSA).
These studies aim to further define
the role of mazdutide in long-term metabolic disease management.
Approved Indications
Mazdutide
is approved for the following indications in adults:
- Long-term weight management
- Glycemic control in type 2 diabetes
These approvals mark an important
step toward more personalized and effective metabolic care.
Scientific Recognition
and Development
The results of the two Phase 3
clinical studies were published consecutively in Nature, one of the world’s
most prestigious scientific journals. Earlier clinical data on mazdutide were
also published in The New England Journal of Medicine (NEJM).
As a result, mazdutide has become
the only GLP-1–based therapy published in both Nature and NEJM, highlighting
its scientific significance and innovation.
About the Company
Mazdutide belongs to Innovent
Biologics, Inc. The development and commercialization of the product are
conducted under an exclusive licensing agreement between Innovent and Eli Lilly
and Company.
Important Note
Innovent does not recommend the use
of any medicinal product outside its approved indications.
Source: PR Newswire – TwoPhase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist)Published Back-to-Back in Nature